Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Happy 4th everyone!
Delighted to share with the our comment just published in the Lancet Oncology on ‘Bridging Classification and Treatment’
Tumor biology > tumor location. It’s time we evolve WHO cancer classification to match how we treat it: by molecular target, not just anatomy
A hybrid model -organ-based AND genomics-driven- can bridge diagnostics and access, accelerating precision care.”
Title: Bridging tumour classification and treatment
Authors: Vivek Subbiah, Benedikt Westphalen, Guiseppe Curigliano, Fabrice Andre
You can read the Full Article on The Lancet Oncology
More posts featuring Cancer Classification.